Life Science News

Amgen (NASDAQ:AMGN) will present at Citi's 2022 Global Healthcare Conference at 8:50 a.m. ET on Wednesday, September 7, 2022 . David M. Reese M.D., executive vice president of Research and Development and Peter H. Griffith executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index.  In 2021, Amgen was named one of the 25 World's Best Workplaces™ by Fortune and Great Place to Work™ and one of the 100 most sustainable companies in the world by Barron's.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen .

CONTACT: Amgen, Thousand Oaks
Megan Fox , 805-447-1423 (media)
Jessica Akopyan , 805-447-0974 (media)
Arvind Sood , 805-447-1060 (investors)

Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-announces-webcast-of-2022-citi-global-healthcare-conference-301617205.html

SOURCE Amgen

News Provided by PR Newswire via QuoteMedia

AMGN
bctx stock

BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors.

Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independent Director for aTyr Pharmaceuticals (Nasdaq: LIFE), a biotechnology company developing novel therapeutics for respiratory diseases and multiple cancer indications.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Esperion Stock Increases After Investors Learn of Short FDA Approval Process

Esperion Therapeutics (NASDAQ:ESPR) shares increased by more than 10% after investors learned that the FDA will not require a long-term outcomes study prior to its potential approval of the company’s cholesterol-lowering drug.
According to Fierce Biotech:

Investors and analysts have been fretting over exactly what the FDA will do with ETC-1002, an LDL-lowering pill that is angling for a share of a blockbuster market many believe lies in wait for a new class of PCSK9 drugs. While the oral ETC-1002 may not be as effective as the PCSK9 drugs, including the newly-approved Praluent from Regeneron ($REGN) and Sanofi ($SNY) as well as a rival Amgen ($AMGN) drug, it also has a shot at grabbing a significant share of the market with a less expensive and more easily managed drug that could do everything many patients in this huge market require.
Overhanging all of these drugs has been a persistent fear that regulators would require a long-running cardiovascular outcomes trial to prove the therapy works as expected in improving patients’ health. But according to Esperion, the agency says it’s ready to give it a green light for a relatively narrow market–which still amounts to a patient pool of 9 million people–and then hold back on a broader approval until after the CVOT data comes in later.

Keep reading...Show less

Gilead Sciences Completes Acquisition of MiroBio

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire MiroBio, a privately held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, for approximately $405 million in cash. The acquisition provides Gilead with MiroBio's proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio's lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) and has entered Phase 1 clinical trials, with the first patient dosed in early August 2022. MB272 targets T, B and dendritic cells to inhibit or blunt activation and suppress an inflammatory immune response.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology Convergence 2022

Five abstracts underscore the long-term safety and efficacy of voclosporin, including in Latino patients and patients with Class V lupus nephritis

Data presentation on pre-clinical asset AUR200 reinforces Aurinia's commitment to autoimmune disease

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
The Gummy Project Announces Plans to Launch 3rd Endangered 'Keystone' Species Gummy Product - Coconut Flavoured Palm Trees

The Gummy Project Announces Plans to Launch 3rd Endangered 'Keystone' Species Gummy Product - Coconut Flavoured Palm Trees

  • After the successful North American launch of Peachy Bees and Watermelon Sharks, the Company has decided to accelerate the launch of Coconut Palm Trees after extensive flavour testing and consumer research.
  • Palm Trees are within GUMY's mandate to support endangered "keystone" species.
  • GUMY to donate a portion of the proceeds from the sale of each bag of Coconut flavoured Palm Trees to a carefully selected conservation partner.
  • Q1 2023 set as launch date for Coconut Palm Trees.

The Gummy Project (CSE: GUMY) (FSE: 0OS) (OTCQB: GUMYF) ("GUMY" or the "Company") is pleased to announce plans to launch a coconut flavoured gummy product that will support Palm Trees, an endangered "keystone" species.

"Following the successful launch of our Peachy Bees and Watermelon Sharks, we want to leverage the strong momentum that we have created with the addition of a new SKU," said Charlie Lamb, President and CEO of GUMY. "From the start, we've been testing a variety of flavours with real consumers, while researching which 'keystone' species we want to support. Palm Trees have been at the top of the list for some time and we are currently in discussions with various conservation groups that support both Palm Trees and rainforests as a whole, with plans to carefully select the ideal partnership in the very near future."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Aurinia Announces European Commission Approval of LUPKYNIS® for the Treatment of Lupus Nephritis

Approval follows the positive opinion granted by European Committee for Medicinal Products for Human Use (CHMP) in July 2022

LUPKYNIS is the first oral medicine approved in both the U.S. and Europe for the treatment of adults living with active lupus nephritis

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

AbbVie Secures Positive CHMP Opinion for Risankizumab for the Treatment of Adults with Moderate to Severe Crohn's Disease

The European Commission decision is expected in the fourth quarter of 2022. This anticipated approval would mark the third indication for risankizumab in the EU

NORTH CHICAGO, Ill. , Sept. 19, 2022 /PRNewswire/ -- ABBVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CMHP) adopted a positive opinion recommending the approval of risankizumab (SKYRIZI ® , 600 mg intravenous [IV] induction and 360 mg subcutaneous [SC] maintenance therapy) for the treatment of adults with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%

Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab

In RELATIVITY-047, Opdualag more than doubled median progression-free survival compared to nivolumab monotherapy

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×